Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21119 | 0.90 | JAK2 (0.52) | JAK2PTK2JAK3 | |
| SCHEMBL15206858 | 0.87 | JAK2 (0.48) | JAK2PTK2JAK3 | |
| SCHEMBL15207847 | 0.87 | KCNH2 (0.47) | JAK2PTK2JAK3CHRNA7ABL1 | |
| SCHEMBL20668 | 0.87 | JAK2 (0.42) | JAK2PTK2JAK3CHRNA7KCNH2 | |
| SCHEMBL31462 | 0.87 | JAK2 (0.49) | JAK2PTK2JAK3 | |
| SCHEMBL15207567 | 0.86 | KIT (0.40) | JAK2PTK2JAK3CHRNA7ABL1 | |
| SCHEMBL30618 | 0.85 | JAK2 (0.52) | JAK2PTK2JAK3 | |
| SCHEMBL19101 | 0.85 | TRPA1 (0.44) | JAK2PTK2JAK3CHRNA7ABL1 | |
| SCHEMBL20546 | 0.84 | JAK2 (0.44) | JAK2PTK2JAK3ABL1KCNH2 | |
| SCHEMBL15207000 | 0.83 | ABL1 (0.42) | JAK2PTK2JAK3CHRNA7ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | JAK2 5/4885PTK2 367/4885JAK3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.